Article Text
PDF
Abstract
Introduction/Background Adropin is a protein that has been found in the brain, liver and peripheral tissues in terms of energy homeostasis. Serum adropin levels were lower in hypertension, diabetes mellitus and metabolic syndrome. The aim of this study was to investigate the relationship between adropin levels, body mass index(BMI) and blood pressure values in endometrial carcinoma(EC).
Minimum (0.01), maximum (2.63, 2.35, 2.68), 25–75% percentile, median (0.75, 0.27, 0.85) and mean (0.99, 0.47, 1.05) serum adropin levels in Type 1 EC, Type 2 EC and control groups.
Methodology 40 healthy individual’s and 50 EC patient’s demographic information including characteristics of obstetric history, diabetes mellitus(DM), hypertension(HT) and family history were recorded. Fasting insulin, homeostasis model assessment for insulin resistance (HOMA-IR), high-density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TC), triglyceride (TG) and adropin levels were obtained from venous blood samples with an overnight fast.
Results There was no statistically significant difference between the control and EC groups at the serum adropin level. However, adropin was found to be significantly lower in type 2 EC (OR=0.350; 95%CI 0.156–0.783; p=0.011). Optimal cut off value was calculated in ROC curve analysis as 0.4 ng/mL for adropin (63.6% sensitivity, 64.7% specificity). Positive Likehood ratio (LR+) was 1.8 and negative Likehood ratio (LR-) was 0.56.
Conclusion In recent years, innovations such as molecular classification recommended for use in the management of endometrial cancer have emerged. Various difficulties such as the high cost to fully transition to clinical use have not been overcome yet, so it does not seem possible to apply it preoperatively to every patient yet. We think that there is still a need for various hormonal methods that are more cost-effective. Further studies may highlight the absolute role of adropin in EC by extending the sample size with different stages of the disease and adding analyses such as molecular or genetic on endometrial tissue.
Disclosures I declare that no funds, grants, or other support were received during the preparation of this manuscript.